Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Circulating prostate tumor cells detected by Reverse transcription-PCR in men with localized or castration-refractory prostate cancer : Concordance with CellSearch assay and association with bone metastases and with survival

Helo, Pauliina ; Cronin, Angel M. ; Danila, Daniel C. ; Wenske, Sven ; Gonzalez-Espinoza, Rita ; Anand, Aseem LU ; Koscuiszka, Michael ; Väänänen, Riina Minna ; Pettersson, Kim and Chun, Felix K.H. , et al. (2009) In Clinical Chemistry 55(4). p.765-773
Abstract

Reverse transcription-PCR (RT-PCR) assays have been used for analysis of circulating tumor cells (CTCs), but their clinical value has yet to be established. We assessed men with localized prostate cancer or castration-refractory prostate cancer (CRPC) for CTCs via real-time RT-PCR assays for KLK3 [kallikrein-related peptidase 3; i.e., prostate-specific antigen (PSA)] and KLK2 mRNAs. We also assessed the association of CTCs with disease characteristics and survival. methods: KLK3, KLK2, and PSCA (prostate stem cell antigen) mRNAs were measured by standardized, quantitative real-time RT-PCR assays in blood samples from 180 localized-disease patients, 76 metastatic CRPC patients, and 19 healthy volunteers. CRPC samples were also tested for... (More)

Reverse transcription-PCR (RT-PCR) assays have been used for analysis of circulating tumor cells (CTCs), but their clinical value has yet to be established. We assessed men with localized prostate cancer or castration-refractory prostate cancer (CRPC) for CTCs via real-time RT-PCR assays for KLK3 [kallikrein-related peptidase 3; i.e., prostate-specific antigen (PSA)] and KLK2 mRNAs. We also assessed the association of CTCs with disease characteristics and survival. methods: KLK3, KLK2, and PSCA (prostate stem cell antigen) mRNAs were measured by standardized, quantitative real-time RT-PCR assays in blood samples from 180 localized-disease patients, 76 metastatic CRPC patients, and 19 healthy volunteers. CRPC samples were also tested for CTCs by an immunomagnetic separation system (CellSearch™; Veridex) approved for clinical use. results: All healthy volunteers were negative for KLK mRNAs. Results of tests for KLK3 or KLK2 mRNAs were positive (≥80 mRNAs/mL blood) in 37 patients (49%) with CRPC but in only 15 patients (8%) with localized cancer. RT-PCR and CellSearch CTC results were strongly concordant (80%-85%) and correlated (Kendall τ, 0.60-0.68). Among CRPC patients, KLK mRNAs and CellSearch CTCs were closely associated with clinical evidence of bone metastases and with survival but were only modestly correlated with serum PSA concentrations.PSCAmRNA was detectedinonly 7 CRPC patients (10%) and was associated with a positive KLK mRNA status. CONCLUSIONS: Real-time RT-PCR assays of KLK mRNAs are highly concordant with CellSearch CTC results in patients with CRPC. KLK2/3-expressing CTCs are common in men with CRPC and bone metastases but are rare in patients with metastases diagnosed only in soft tissues and patients with localized cancer.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical Chemistry
volume
55
issue
4
pages
765 - 773
publisher
American Association for Clinical Chemistry
external identifiers
  • scopus:64149123523
  • pmid:19233911
ISSN
0009-9147
DOI
10.1373/clinchem.2008.117952
language
English
LU publication?
no
id
2985c74d-667b-4095-80e5-ee34c6ac5eb3
date added to LUP
2022-12-08 12:31:57
date last changed
2024-04-03 10:16:01
@article{2985c74d-667b-4095-80e5-ee34c6ac5eb3,
  abstract     = {{<p>Reverse transcription-PCR (RT-PCR) assays have been used for analysis of circulating tumor cells (CTCs), but their clinical value has yet to be established. We assessed men with localized prostate cancer or castration-refractory prostate cancer (CRPC) for CTCs via real-time RT-PCR assays for KLK3 [kallikrein-related peptidase 3; i.e., prostate-specific antigen (PSA)] and KLK2 mRNAs. We also assessed the association of CTCs with disease characteristics and survival. methods: KLK3, KLK2, and PSCA (prostate stem cell antigen) mRNAs were measured by standardized, quantitative real-time RT-PCR assays in blood samples from 180 localized-disease patients, 76 metastatic CRPC patients, and 19 healthy volunteers. CRPC samples were also tested for CTCs by an immunomagnetic separation system (CellSearch™; Veridex) approved for clinical use. results: All healthy volunteers were negative for KLK mRNAs. Results of tests for KLK3 or KLK2 mRNAs were positive (≥80 mRNAs/mL blood) in 37 patients (49%) with CRPC but in only 15 patients (8%) with localized cancer. RT-PCR and CellSearch CTC results were strongly concordant (80%-85%) and correlated (Kendall τ, 0.60-0.68). Among CRPC patients, KLK mRNAs and CellSearch CTCs were closely associated with clinical evidence of bone metastases and with survival but were only modestly correlated with serum PSA concentrations.PSCAmRNA was detectedinonly 7 CRPC patients (10%) and was associated with a positive KLK mRNA status. CONCLUSIONS: Real-time RT-PCR assays of KLK mRNAs are highly concordant with CellSearch CTC results in patients with CRPC. KLK2/3-expressing CTCs are common in men with CRPC and bone metastases but are rare in patients with metastases diagnosed only in soft tissues and patients with localized cancer.</p>}},
  author       = {{Helo, Pauliina and Cronin, Angel M. and Danila, Daniel C. and Wenske, Sven and Gonzalez-Espinoza, Rita and Anand, Aseem and Koscuiszka, Michael and Väänänen, Riina Minna and Pettersson, Kim and Chun, Felix K.H. and Steuber, Thomas and Huland, Hartwig and Guillonneau, Bertrand D. and Eastham, James A. and Scardino, Peter T. and Fleisher, Martin and Scher, Howard I. and Lilja, Hans}},
  issn         = {{0009-9147}},
  language     = {{eng}},
  month        = {{04}},
  number       = {{4}},
  pages        = {{765--773}},
  publisher    = {{American Association for Clinical Chemistry}},
  series       = {{Clinical Chemistry}},
  title        = {{Circulating prostate tumor cells detected by Reverse transcription-PCR in men with localized or castration-refractory prostate cancer : Concordance with CellSearch assay and association with bone metastases and with survival}},
  url          = {{http://dx.doi.org/10.1373/clinchem.2008.117952}},
  doi          = {{10.1373/clinchem.2008.117952}},
  volume       = {{55}},
  year         = {{2009}},
}